Related Experiment Video
Updated: Mar 31, 2026

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
Specific treatment for cancer-associated thrombosis
Mike Laffan1,2, Gemma Westcott
1Department of Haematology, Imperial College London, London, SW7 2AZ, UK.
Abstract:
Mike Laffan speaks to Gemma Westcott, Commissioning Editor: Michael Laffan is Professor of Haemostasis and Thrombosis in the Department of Haematology at Imperial College, London, UK, and Director of the Hammersmith Hospital Haemophilia Centre. He trained in medicine at Oxford University and hematology at the Hammersmith and Royal Free hospitals in London. His principal research interests are the structure-function relationship of von Willebrand factor, in particular the role of glycosylation, and the mechanisms and regulation of thrombin generation. He has published extensively on hemostasis and recently edited the 11th edition of Practical Haematology. He also served on NEQAS and the British Committee for Standards in Haematology Task force on Haemostasis and Thrombosis.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

